#-207 IGF-1 LR3

 

 

Synthetic peptide IGF-1 LR3 is lengthened analogue of endogenous peptide hormone IGF-1 (human insulin-like growth factor 1). Unlike regular IGF-1, its prolonged version IGF-1 LR3 haves an arginine instead of a glutamic acid at the third position in its amino acid sequence (“arginine 3”), and also has an additional 13 amino acids at its N-terminus (MFPAMPLLSLFVN) (“long”). Total length of its amino acid chain is 83 amino acids unlike 70 amino acids of regular IGF-1.

 

IGF-1 LR3 still retains its strong pharmacological activity as an agonist of the IGF-1 receptor, but due to the mentioned modifications has very low affinity for the insulin-like growth factor-binding proteins (IGFBPs) unlike regular IGF-1 does have, and also has improved metabolic stability. As a result, it is approximately three times more potent than IGF-1, and possesses a significantly longer half-life of about 20 hours. 

 

Clinical trials have shown, that IGF-1 LR3 binds with high-affinity to IGF-1 receptor (IGF1R), and due to its significantly reduced binding to IGF-binding proteins, is even more metabolic stable and potent than regular IGF-1 in stimulating hypertrophy and proliferation of cells. IGF-1 LR3 can be suitable treatment in catabolic states (using the peptide to induce anabolism in catabolic conditions such as muscular dystrophy). IGF-1 has a strong ability to maintain and build muscle. In addition to a direct anabolic effect on skeletal muscle, the production of more IGF-I is also capable of stimulating the proliferation and differentiation of muscle stem cells (satellite cells) – real growth of new muscle cells. Peptide hormone IGF-1 is the only hormone that can do this.

 

Overall regeneration of the whole body (incl. internal organs), increased cellular repair;

Anti-aging effects, rejuvenation and the ability to slow-down the aging;

Increased collagen production, healthier skin, helping to smooth out wrinkles;

Strong anabolic effect / promoting muscle growth, strength and performance;

Ability to induce muscle hyperplasia – the growth of new muscle cells;

Strong anti-catabolic effect / protection against muscle wasting;

Increased bone mineral content / greater bone mineral density;

Improved cognitive functions, improves learning and memory;

Promotes regeneration of the nervous system and brain health;

May reduce risk of heart & cardio-vascular diseases;

Strengthened immune system;

Anti-inflammatory effects;

Improved gut health

 

Possible correlation insulin-like growth factor 1 to certain forms of cancer development (however, performed studies are often unclear, and often with conflicting or very different results)

Risk for diabetes (performed studies are often unclear)

Low blood sugar/Joint pain/Nausea/Acne

 

 

 

NO: Use of IGF-1 products is banned by the United States Anti-Doping Agency, World Anti-Doping Agency, and most professional sports organizations. IGF-1 is also on the OPSS list of DoD-prohibited substances, so Military Service Members should avoid products with this ingredient.

 

YES: IGF-1 has a strong ability to promote muscle growth, especially DES(1-3) IGF-1 form. In addition to a direct anabolic effect on skeletal muscle, the production of more IGF-1 is also capable of stimulating the proliferation and differentiation of muscle stem cells (satellite cells) – real growth of new muscle cells (IGF-1 is the only hormone that can do this). Due from this properties it is very promising candidate for treat catabolic diseases such as muscular dystrophy etc.

 

IGF-1 LR3 does have elimination Half-Life about 20 hours.

 

One study reports the median serum IGF-I level is about 370 ng/ml at the age of 18. The European Prospective Investigation into Cancer and Nutrition (EPIC) study reported an average serum IGF-1 level of 200-210 ng/ml, suggesting that this is a typical level for adults on a Western diet. Low IGF-1 levels associated with an increased risk of disease or mortality are generally about 70-80 ng/ml or lower.

 

UNCLEAR: Studies showed that low and high IGF-I levels are related to impaired glucose tolerance and to a higher risk of type 2 diabetes.

 

YES: Insulin-like growth factor 1 (IGF-1) and growth hormone (GH) interact with insulin to modulate its control of carbohydrate metabolism. New studies shows that blocking the effect of GH in the presence of low serum IGF-1 concentrations enhances insulin sensitivity.

 

MAY: IGF-I treatment may cause fluid and sodium retention.

 

YES: All milk based products, whether they’re non organic dairy products or organic milk and organic cheese, contain a certain amount of IGF-1.

 

The name insulin-like growth factor reflects the fact that these substances have insulin-like actions in some tissues, though they are far less potent than insulin in decreasing blood glucose concentrations.

 

YES: Insulin inhibits growth hormone signaling via the growth hormone receptor/JAK2/STAT5B pathway.

 

The hypothalamic growth hormone (GH)-releasing hormone (GHRH) promotes non-rapid eye movement sleep (NREMS). Insulin-like growth factor-1 (IGF-1) acts as a negative feedback in the somatotropic axis inhibiting GHRH and stimulating somatostatin.

 

There is no widely available urine test for IGF-1, but like human growth hormone, IGF-1 can be detected in blood tests.

 

Whey protein stimulates fasting insulin and casein stimulates circulating IGF-1. Both milk protein fractions seem to be important, but different, in the growth-stimulating effect of milk.

 

It is hypothesized that testosterone might induce the synthesis of IGF-1 which could affect cell proliferation.

 

A somatomedin C test, also called an insulin-like growth factor-1 (or IGF-1) test, helps doctors evaluate whether a person is producing a normal amount of human growth hormone (hGH, or somatotropin).

 

In scientific and clinical studies doses of IGF-1 LR3 are mentioned as 20-100 mcg per day.

 

IGF-1 LR3 is prolonged version of endogenous peptide hormone IGF-1 (human insulin-like growth factor 1). It is strong agonist of the IGF-1 receptor, but with very low affinity for the insulin-like growth factor-binding proteins (IGFBPs) unlike regular IGF-1. As a result, it is approximately three times more potent than regular IGF-1. IGF-1 LR3 can be suitable treatment in catabolic states and diseases (such as muscular dystrophy). Because has a strong ability to maintain and build muscle. The production of more IGF-1 is also capable of stimulating the proliferation and differentiation of muscle stem cells.